Phaseline

Targets › IL1RN

IL1RN (Interleukin-1 receptor antagonist protein): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout Nov 2026.

Anti-inflammatory antagonist of interleukin-1 family of pro-inflammatory cytokines such as interleukin-1beta/IL1B and interleukin-1alpha/IL1A. Protects from immune dysregulation and uncontrolled systemic inflammation triggered by IL1 for a range of innate stimulatory agents such as pathogens. (UniProt, P18510)

Open in Phaseline: the race on IL1RN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Pacira PharmaceuticalsFX201 (humantakinogene hadenovec)
interleukin-1 receptor antagonist (IL-1Ra) gene therapy
IL1RNPhase 1Osteoarthritis, KneeNov 2026

Conditions

Osteoarthritis, Knee (1)

Modalities

protein or peptide (1)

Companies

Pacira Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.